Chugai to launch translational research division

Chugai Pharma has announced that it will establish a new division from April 1, specialising in early clinical development to accelerate the generation of proof-of-concept for in-house drug candidates.

Chugai’s mid-term management plan “ACCEL 15”, sets “Acceleration of global development” as one of the top priority challenges. Newly establishing the Translational Clinical Research Division as one of the measures to address those challenges will enable to build a development setup equipped with top-level quality and speed in the world, which would allow Chugai to obtain proof-of-concept at an earlier stage.